INFI Infinity Pharmaceuticals Inc.

1.45
+0.28  (+24%)
Previous Close 1.17
Open 1.2
Price To Book 4.39
Market Cap 82,692,007
Shares 57,028,970
Volume 979,122
Short Ratio
Av. Daily Volume 129,939
Stock charts supplied by TradingView

NewsSee all news

  1. Infinity Pharmaceuticals Provides 2020 Goals and Financial Guidance

    - Recent Non-Dilutive Financing Extends Cash Runway into 2H 2021 and Fully Funds All Ongoing IPI-549 Clinical Trials Through Key Data Readouts - - MARIO-275 Global, Randomized, Controlled Phase 2 Study in Urothelial

  2. Infinity Pharmaceuticals Raises $20 Million Through an Innovative Non-Dilutive Asset-Backed Financing from BVF

    -- Fully funds all ongoing IPI-549 clinical trials through key data readouts -- -- Non-dilutive financing extends cash runway into 2H 2021 -- Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") today announced

  3. Infinity Pharmaceuticals to Present Corporate Overview at 38th Annual J.P. Morgan Global Healthcare Conference

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced today that Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals, will provide a corporate overview at the 38th Annual J.P. Morgan Global

  4. Infinity Pharmaceuticals Provides Company Update and Third Quarter 2019 Financial Results

    -- MARIO-1 Enrollment Completion Expected in 2019 and Data Presentation Expected in 2020 -- -- MARIO-3 Enrollment Completion and Data Presentation Expected in 2020 -- -- MARIO-275 Enrollment Completion Expected in

  5. Infinity Announces the Date of Its Third Quarter 2019 Financial Results Conference Call and Webcast

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will host a conference call on Wednesday, October 30, 2019 at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on the company. A live

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/1b data due in 2020.
IPI-549 + Nivolumab (MARIO-1)
Solid tumors
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
Phase 2 enrolment completed. Does not plan to further development
Retaspimycin Hydrochloride with everolimus
Cancer - NSCLC
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis
Phase 1 initiation announced September 4, 2019.
AB298 + IPI-549 + Doxil
Triple negative breast cancer (TNBC) and ovarian cancer
Phase 2 data due mid-2021.
IPI-549 + Nivolumab (MARIO-275)
Urothelial cancer
Phase 2 data due in 2020.
IPI-549 + Tecentriq and Abraxane and IPI-549 + Tecentriq and Avastin (MARIO-3)
Front-line triple negative breast cancer (TNBC); Renal cell cancer (RCC)

Latest News

  1. Infinity Pharmaceuticals Provides 2020 Goals and Financial Guidance

    - Recent Non-Dilutive Financing Extends Cash Runway into 2H 2021 and Fully Funds All Ongoing IPI-549 Clinical Trials Through Key Data Readouts - - MARIO-275 Global, Randomized, Controlled Phase 2 Study in Urothelial

  2. Infinity Pharmaceuticals Raises $20 Million Through an Innovative Non-Dilutive Asset-Backed Financing from BVF

    -- Fully funds all ongoing IPI-549 clinical trials through key data readouts -- -- Non-dilutive financing extends cash runway into 2H 2021 -- Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") today announced

  3. Infinity Pharmaceuticals to Present Corporate Overview at 38th Annual J.P. Morgan Global Healthcare Conference

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced today that Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals, will provide a corporate overview at the 38th Annual J.P. Morgan Global

  4. Infinity Pharmaceuticals Provides Company Update and Third Quarter 2019 Financial Results

    -- MARIO-1 Enrollment Completion Expected in 2019 and Data Presentation Expected in 2020 -- -- MARIO-3 Enrollment Completion and Data Presentation Expected in 2020 -- -- MARIO-275 Enrollment Completion Expected in

  5. Infinity Announces the Date of Its Third Quarter 2019 Financial Results Conference Call and Webcast

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will host a conference call on Wednesday, October 30, 2019 at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on the company. A live

  6. Infinity Pharmaceuticals Announces the Initiation of Two Clinical Trials Evaluating IPI-549 in Novel Triple Combination Therapies for the Treatment of Solid Tumors

    CAMBRIDGE, Mass., Sept. 4, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) today announced the initiation of two clinical trials for IPI-549, a first-in-class, oral immuno-oncology product candidate

  7. Infinity to Present at Two Upcoming Conferences in September

    CAMBRIDGE, Mass., Sept. 3, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that

  8. Infinity Pharmaceuticals Announces Transition of Samuel Agresta, M.D., from Chief Medical Officer to Board of Directors

    CAMBRIDGE, Mass., Aug. 22, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) today announced that Samuel Agresta, M.D., will transition from his role as Chief Medical Officer to Infinity's Board